Bristol-Myers Squibb signed agreements with ICON and PAREXEL for joint strategic, operational and capability support of the company’s clinical development program. ICON and PAREXEL will provide global support for the execution of BMS’ clinical studies to support its full development pipeline during the next three years. BMS is preparing for a large volume of clinical development work that will require expanding upon its existing partnering approach for clinical development, due to growt...